Kintara Therapeutics (formerly DelMar Pharmaceuticals) Returns Compliant with NASDAQ Minimum Offer Price Requirement

SAN DIEGO, Aug 21, 2020 / PRNewswire / – Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (“Kintara” or the “Company”) (Nasdaq: KTRA) today announced that it is once again in compliance with the requirement minimum bid price for continued listing on the NASDAQ Capital Market in accordance with Listing Rule 5550 (a) (2) (the “Minimum Bid Rule”). At August 19, 2020, Kintara received a letter from The Nasdaq Stock Market, Inc.’s Quotation Qualification Department stating that because Kintara’s shares had a closing bid price equal to or greater than $ 1.00 per share for a minimum of ten (10) consecutive business days, Kintara’s shares again complied with the minimum bid price rule and the matter is now closed.

About Kintara

Situated in San diego, california, Kintara is dedicated to developing new cancer therapies for patients with unmet medical needs.

Kintara is developing two advanced stage therapies ready for phase 3 for clearly unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC.

VAL-083 is a “first-in-class” small molecule chemotherapy with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including tumors of the central nervous system, ovarian and other solid tumors (eg, NSCLC, cancer of the bladder, head and neck) in clinical trials in the United States sponsored by the National Cancer Institute (NCI). Based on Kintara’s internal research programs and these previous NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

Kintara is also advancing its proprietary advanced stage photodynamic therapy (PDT) platform, which shows promise as a localized treatment of skin or visceral tumors as well as other potential indications. REM-001 therapy has already been studied in four phase 2/3 clinical trials in patients with CMBC who had previously received unsuccessful chemotherapy and / or radiation therapy. With a clinical efficacy to date of 80% complete CMBC evaluable lesion responses and with an existing robust safety database of approximately 1,100 patients in multiple indications, Kintara is advancing the REM-001 CMBC program into testing advanced stage pivots.

Forward-looking statements

This press release contains forward-looking statements based on Kintara’s current expectations. This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by words such as “may”, “should”, “expects”, “plans”, “Foresees,” “might”, “intends”, “targets”, “projects”, “contemplates”, “believes”, “estimates”, “predicts”, “potential” or “continues” or the negative these or other similar words. These statements are only predictions. Kintara has based these forward-looking statements in large part on its then current expectations and projections regarding future events, as well as on the beliefs and assumptions of management Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond Kintara’s control, and actual results could differ materially from those stated or implied in the forward-looking statements. es due to a number of factors including, but not limited to: (i) risks associated with the impact of the COVID-19 pandemic; (ii) the risks and uncertainties associated with Kintara’s ability to develop, market and sell products based on its technology; the expected benefits and effectiveness of Kintara’s products and technology; the availability of substantial additional funding for Kintara to continue operations and to conduct research and development, clinical studies and future product commercialization; and, Kintara’s business, research, product development, regulatory approval, marketing and distribution plans and strategies (ii) the successful completion of the recently completed merger with Adgero Biopharmaceuticals, and (iii) detailed risks in Kintara’s most recent annual report on Form 10 -K and subsequent reports filed with the SEC, as well as other documents which may be filed by Kintara from time to time with the SEC. Therefore, you should not rely on forward-looking statements as predictions of future events. Kintara cannot assure you that events and circumstances reflected in forward-looking statements will materialize or occur, and actual results could differ materially from those projected in forward-looking statements. The forward-looking statements made in this communication relate only to events that occurred on the date the statements are made. Unless required by applicable law or regulation, Kintara does not undertake to update a forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unforeseen events. . Investors should not assume that the failure to update a previously published “forward-looking statement” constitutes a reaffirmation of that statement.

Contact details

[email protected]

Jules Abraham
Public relations manager
[email protected]

Cision Show original content:

SOURCE Kintara Therapeutics

Source link

Previous Rishi Sunak's half-price offer is a boost for Indian restaurants in Britain
Next TAOP regains compliance with the Nasdaq minimum offer price

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *